Journal of Infection
Volume 61, Issue 2 , Pages 150-154 , August 2010

Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China

,Accepted 2 May 2010.

References 

  1. Feuerriegel S, Cox HS, Zarkua N, Karimovich HA, Braker K, Rusch-Gerdes S, et al. Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob Agents Chemother. 2009;53:3353–3356
  2. Andersson MI, MacGowan AP. Development of the quinolones. J of Antimicrob Chemother. 2003;51(Suppl. 1):1–11
  3. Emmerson AM, Jones AM. The quinolones: decades of development and use. J Antimicrob Chemother. 2003;51(Suppl. 1):13–20
  4. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother. 2007;59:860–865
  5. Mohanty KC, Dhamgaye TM. Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis. Chest. 1993;104:1194–1198
  6. Sirgel FA, Botha FJ, Parkin DP, Van de wal BW, Schall R, Donald PR, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med. 1997;156:901–905
  7. Vacher S, Pellegrin JL, Leblanc F, Fourche J, Maugein J. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin. J Antimicrob Chemother. 1999;44:847–852
  8. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51:576–582
  9. Akcali S, Surucuoglu S, Cicek C, Ozbakkaloglu B. In vitro activity of ciprofloxacin, ofloxacin and levofloxacin against Mycobacterium Tuberculosis. Ann Saudi Med. 2005;25:409–412
  10. Piersimoni C, Lacchini C, Penati V, Iona E, Fattorini L, Nista D, et al. Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxaxin. Diagn Microbiol Infect Dis. 2007;57:283–287
  11. Sun Z, Zhang J, Zhang X, Wang S, Zhang Y, Li C. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int J Antimicrob Agents. 2008;31:115–121
  12. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852–857
  13. Xu P, Li X, Zhao M, Gui X, DeRiemer K, Gagneux S, et al. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob Agents Chemother. 2009;53:3170–3172
  14. Ruiz J. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J Antimicrob Chemother. 2003;51:1109–1117
  15. Aubry A, Veziris N, Cambau E, Truffo-Perrot C, Jariler V, Fisher LM. Novel gyrase mutations in quinolone and – hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob Agents Chemother. 2008;50:104–112
  16. Chu DT, Fernandes PB. Structure-activity relationships of the fluoroquinolones. Antimicrob Agents Cheomther. 1989;33:131–135
  17. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997;61:377–392
  18. Hooper DC. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis. 2000;31(Suppl. 2):S24–S28
  19. Hawkey PM. Mechanisms of quinolone action and microbial response. J Antimicrob Chemother. 2003;51(Suppl. 1):29–35
  20. Chen FJ, Lo HJ. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect. 2003;36:1–9
  21. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zenchiedrich L. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob Agents Chemother. 2009;53:235–241
  22. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother. 1994;38:773–780
  23. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother. 1998;42:2084–2088
  24. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J Clin Microbiol. 2006;44:4566–4568
  25. Chan RC, Hui M, Chan EW, Au TK, Chin ML, Yip CK, et al. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. J Antimicrob Chemother. 2007;59:866–873
  26. Umubyeyi AN, Rigouts L, Shamputa IC, Fissette K, de Rijk PW, Strulens MJ, et al. Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. J Antimicrob Chemother. 2007;59:1031–1033
  27. Mokrousov I, Otten T, Manichva O, Potapova Y, Vishnevsky B, Narvskaya O, et al. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother. 2008;52:2937–2939
  28. Ball P. Quinolone generations: natural history or natural selection?. J Antimicrob Chemother. 2000;46(Suppl. 3):17–24
  29. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest. 2000;117:744–751
  30. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest. 2003;124:1476–1481
  31. Marrra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest. 2005;128:1406–1413
  32. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995–2003. J Antimicrob Chemother. 2005;56:1058–1062
  33. Siddiqi N, Shamim M, Hussain S, Choudhary KR, Ahmed N, Prachee , et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from Patients in North India. Antimicrob Agents Chemother. 2002;46:443–450
  34. Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Permot C, Camuset J, et al. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother. 2008;50:4170–4173

PII: S0163-4453(10)00132-5

doi: 10.1016/j.jinf.2010.05.001

Journal of Infection
Volume 61, Issue 2 , Pages 150-154 , August 2010

Article Tools